Study Milestones
In June 2009, Longevica co-founder Alexander Chikunov organized a workshop and invited renowned scientists exploring novel approaches to life extension, including Alexey Ryazanov, Ph.D., Professor of Pharmacology, Rutgers University. Following the workshop, Alexander committed to investing in experiments based on Dr. Ryazanov's ideas and ground-breaking discoveries. Additionally, Alexander financed three other leading scientific concepts.
Dr. Ryazanov proposed an innovative idea of blind testing of a vast number of pharmacological compounds in long-lived mice to find compounds or pharmacological classes with measurable life extension effects. An agnostic and practical approach characterizes this experiment.
The study was the most extensive experiment of its kind, with 20,000 long-lived female mice and 1,033 pharmacological compounds, including drugs, drug-like molecules, vitamins, supplements, food additives, and natural compounds.
The experiment was conducted at the Jackson Laboratory, Sacramento, US, a leading life science and pharmaceutical industry laboratory.
In mid-2013, our nearly four-year experiment concluded (1,406 days) and it soon became clear that the findings were remarkable. At the end of 2013, Alexander moved to Princeton to develop this research together with Dr. Ryazanov and the team.
Study Results
Five compounds demonstrated a statistically significant life extension effect by 16-22%, the second-best performing result since the discovery of rapamycin.
Harnessing big data analysis of the 1,033 compounds representing 62 pharmacological classes, we identified several particular classes of compounds with statistically significant life-extension effects, pointing to the existence of new life extension mechanisms.
Three Mechanisms of Action
In 2020, the Longevica research team established a valid hypothesis explaining three mechanisms of life extension.
In 2022, we are launching a new large-scale research study to test 300 compounds in the most promising classes found by our team, to be conducted at Jackson Laboratory.
Open Innovation Platform
We are also launching an open innovation platform that will allow scientists and research institutions from across the world to test drugs of their choice in full-scale pharmacological screening experiments. Our platform will provide control groups while managing operations and administrative costs, making screening trials significantly more affordable. The entire Longevica dataset will be open for data mining, experimentation, and analysis to researchers on the platform in real time.
With open innovation, Longevica aims to remove traditional barriers that impede research, and foster collaboration and experiment data collection and analysis with an ecosystem designed to expedite breakthrough discoveries in our field.
Connect with us
